Diagnostic utility of RAS mutation testing for refining cytologically indeterminate thyroid nodules

Abstract: RAS mutations are prevalent in indeterminate thyroid nodules, but their association with malignancy risk and utility for diagnosis remains unclear. We performed a systematic review and meta-analysis to establish the clinical value of RAS mutation testing for cytologically indeterminate thyroid nodules. PubMed and Embase were systematically searched for relevant studies. Thirty studies comprising 13,328 nodules met the inclusion criteria. Random effects meta-analysis synthesized pooled estimates of RAS mutation rates, risk of malignancy with RAS positivity, and histologic subtype outcomes. The pooled mutation rate was 31 % (95 % CI 19-44 %) among 5,307 indeterminate nodules. NRAS mutations predominated at 67 % compared to HRAS (24 %) and KRAS (12 %). The malignancy rate with RAS mutations was 58 % (95 %CI=48-68 %). RAS positivity increased malignancy risk 1.7-fold (RR 1.68, 95 %CI=1.21-2.34, p=0.002), with significant between-study heterogeneity (I2=89 %). Excluding one outlier stud.... https://www.excli.de/index.php/excli/article/view/6975

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Diagnostic utility of RAS mutation testing for refining cytologically indeterminate thyroid nodules ; volume:23 ; year:2024 ; EXCLI journal ; 23 (2024)

Contributors, Places and Time

• Creator: Riccio, Isabel R. ; LaForteza, Alexandra C. ; Hussein, Mohammad H. ; Linhuber, Joshua P. ; Issa, Peter P. ; Staav, Jonathan ; Fawzy, Manal Said ; Toraih, Eman A. ; Kandil, Emad

Further information

• DOI: 10.17179/excli2024-6975
• URN: urn:nbn:de:101:1-2024030802152051474750
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 14.08.2025, 10:47 AM CEST